1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsResearch Project Grant (R01) to identify etiopathogenetic commonalities between lung cancer and Chronic Obstructive Pulmonary Disease (COPD) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) and National Cancer Institute (NCI). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-HL-11-002 Funding Opportunity Title:Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Expected Number of Awards:8 Assistance Listings:93.
393 -- Cancer Cause and Prevention Research 93. 396 -- Cancer Biology Research 93.
838 -- Lung Diseases Research Cost Sharing or Matching Requirement:No Original Closing Date for Applications:Jun 18, 2010 Current Closing Date for Applications:Jun 18, 2010 Archive Date:Jul 19, 2010 Estimated Total Program Funding:$ 24,000,000 Eligible Applicants:For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Public and State controlled institutions of higher education City or township governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
## Additional Information Agency Name:National Institutes of Health Description:Purpose.
This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute and the National Cancer Institute, National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/organizations to identify the fundamental etiopathogenetic commonalities between lung cancer and Chronic Obstructive Pulmonary Disease (COPD) in order to characterize: (a) the genotypic and phenotypic characteristics that determine individual susceptibility; and (b) the shared biochemical, molecular, and immunological pathways involved in the origin and progression of the two diseases.
Mechanism of Support. This FOA will utilize the Research Project Grant (R01) award mechanism. Funds Available and Anticipated Number of Awards.
The NHLBI intends to commit up to $12,000,000 (Total Costs) and the NCI intends to commit up to $12,000,000 (Total Costs) over 4 years. It is anticipated that up to 8 awards will be made. Link to Additional Information:http://grants.
nih. gov/grants/guide/rfa-files/RFA-HL-11-002. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes.
To continue working, click on the "OK" button below. This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: Institutions/organizations are eligible to apply. This FOA utilizes the Research Project Grant (R01) award mechanism. Confirm the full requirements in the official notice before applying.
The current listing shows up to $12,000,000 (Total Costs) from NHLBI and up to $12,000,000 (Total Costs) from NCI over 4 years; anticipated up to 8 awards. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Research Project Grant (R01) to identify etiopathogenetic commonalities between lung cancer and Chronic Obstructive Pulmonary Disease (COPD) is funded by National Heart, Lung, and Blood Institute (NHLBI) and National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articleOn May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe $46M FSHARP program is creating shelf-stable synthetic blood from freeze-dried components. A new SWiFT SBIR topic opened May 6 for autonomous field transfusion devices. What grant seekers in biomedical engineering need to know.
Read article